Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
96 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Actinic (Solar) Keratosis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H1 2015', provides an overview of the Actinic (Solar) Keratosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Actinic (Solar) Keratosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Actinic (Solar) Keratosis Overview 9 Therapeutics Development 10 Pipeline Products for Actinic (Solar) Keratosis - Overview 10 Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11 Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12 Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 14 Actinic (Solar) Keratosis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Actinic (Solar) Keratosis - Products under Development by Companies 19 Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 21 Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 22 3M Drug Delivery Systems 22 Advancell 23 Biofrontera AG 24 Clinuvel Pharmaceuticals Limited 25 Digna Biotech, S.L. 26 Dolorgiet Gmbh & Co. Kg 27 Foamix Pharmaceuticals Ltd. 28 G&E Herbal Biotechnology Co., Ltd. 29 Galderma S.A. 30 Kinex Pharmaceuticals, LLC 31 LEO Pharma A/S 32 Novartis AG 33 Novelix Pharmaceuticals, Inc. 34 Promius Pharma, LLC 35 RestorGenex Corporation 36 Spherium Biomed S.L. 37 Actinic (Solar) Keratosis - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 854-A - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 ACT-01 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AD-17137 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 afamelanotide - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AK-3012 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 aminolevulinic acid hydrochloride - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ANs-40 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ANS-401 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ANS-403 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CUV-9900 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 disitertide - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 imiquimod - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 KX-01 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 LEO-43204 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 LFX-453 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NVX-207 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 P-529 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 resiquimod - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecules to Activate Protein Kinase C for Dermatology and Cancer - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SP-12054 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 SRT-100 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 sulindac + hydrogen peroxide - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Actinic (Solar) Keratosis - Recent Pipeline Updates 77 Actinic (Solar) Keratosis - Dormant Projects 85 Actinic (Solar) Keratosis - Discontinued Products 87 Actinic (Solar) Keratosis - Product Development Milestones 88 Featured News & Press Releases 88 Jan 26, 2015: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz 88 Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 88 Nov 26, 2014: Further Progress In International Approval Processes Of Biofrontera's Ameluz 89 Oct 24, 2014: Europe Approves Novel Australian Drug Developed for Rare Sun Disease 89 Oct 08, 2014: US Regulatory Authority Gives Green Light To Proposed Approach Towards Approval Of Ameluz In The USA 90 Oct 02, 2014: Clinical Program For US Approval Of Ameluz Approaches Completion: Studies Confirm Excellent Efficacy And Safety 91 Aug 21, 2014: Biofrontera AG: Pre-NDA meeting scheduled with FDA for the approval of Ameluz and B-RhodoLED 92 Aug 20, 2014: Biofrontera files litigation against former supplier 92 Aug 11, 2014: Ameluz has passed first stage in approval process in Israel 93 Aug 06, 2014: Biofrontera AG: First Ameluz Sales In Central Eastern European Region 93 Appendix 95 Methodology 95 Coverage 95 Secondary Research 95 Primary Research 95 Expert Panel Validation 95 Contact Us 95 Disclaimer 96
List of Tables Number of Products under Development for Actinic (Solar) Keratosis, H1 2015 10 Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Investigation by Universities/Institutes, H1 2015 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Comparative Analysis by Unknown Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H1 2015 22 Actinic (Solar) Keratosis - Pipeline by Advancell, H1 2015 23 Actinic (Solar) Keratosis - Pipeline by Biofrontera AG, H1 2015 24 Actinic (Solar) Keratosis - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2015 25 Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H1 2015 26 Actinic (Solar) Keratosis - Pipeline by Dolorgiet Gmbh & Co. Kg, H1 2015 27 Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 28 Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015 29 Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H1 2015 30 Actinic (Solar) Keratosis - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 31 Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2015 32 Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2015 33 Actinic (Solar) Keratosis - Pipeline by Novelix Pharmaceuticals, Inc., H1 2015 34 Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H1 2015 35 Actinic (Solar) Keratosis - Pipeline by RestorGenex Corporation, H1 2015 36 Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H1 2015 37 Assessment by Monotherapy Products, H1 2015 38 Assessment by Combination Products, H1 2015 39 Number of Products by Stage and Target, H1 2015 41 Number of Products by Stage and Mechanism of Action, H1 2015 43 Number of Products by Stage and Route of Administration, H1 2015 45 Number of Products by Stage and Molecule Type, H1 2015 47 Actinic (Solar) Keratosis Therapeutics - Recent Pipeline Updates, H1 2015 77 Actinic (Solar) Keratosis - Dormant Projects, H1 2015 85 Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H1 2015 86 Actinic (Solar) Keratosis - Discontinued Products, H1 2015 87
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.